Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer - PubMed (original) (raw)
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
E E Cameron et al. Nat Genet. 1999 Jan.
Abstract
Densely methylated DNA associates with transcriptionally repressive chromatin characterized by the presence of underacetylated histones. Recently, these two epigenetic processes have been dynamically linked. The methyl-CpG-binding protein MeCP2 appears to reside in a complex with histone deacetylase activity. MeCP2 can mediate formation of transcriptionally repressive chromatin on methylated promoter templates in vitro, and this process can be reversed by trichostatin A (TSA), a specific inhibitor of histone deacetylase. Little is known, however, about the relative roles of methylation and histone deacetylase activity in the stable inhibition of transcription on densely methylated endogenous promoters, such as those for silenced alleles of imprinted genes, genes on the female inactive X chromosome and tumour-suppressor genes inactivated in cancer cells. We show here that the hypermethylated genes MLH1, TIMP3 (TIMP3), CDKN2B (INK4B, p15) and CDKN2A (INK4, p16) cannot be transcriptionally reactivated with TSA alone in tumour cells in which we have shown that TSA alone can upregulate the expression of non-methylated genes. Following minimal demethylation and slight gene reactivation in the presence of low dose 5-aza-2'deoxycytidine (5Aza-dC), however, TSA treatment results in robust re-expression of each gene. TSA does not contribute to demethylation of the genes, and none of the treatments alter the chromatin structure associated with the hypermethylated promoters. Thus, although DNA methylation and histone deacetylation appear to act as synergistic layers for the silencing of genes in cancer, dense CpG island methylation is dominant for the stable maintenance of a silent state at these loci.
Similar articles
- Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer.
Kondo Y, Shen L, Issa JP. Kondo Y, et al. Mol Cell Biol. 2003 Jan;23(1):206-15. doi: 10.1128/MCB.23.1.206-215.2003. Mol Cell Biol. 2003. PMID: 12482974 Free PMC article. - DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes in ovarian cancer cells.
Meng CF, Su B, Li W. Meng CF, et al. Mol Med Rep. 2011 Nov-Dec;4(6):1273-8. doi: 10.3892/mmr.2011.557. Epub 2011 Aug 16. Mol Med Rep. 2011. PMID: 21850374 - Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
Magdinier F, Wolffe AP. Magdinier F, et al. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4990-5. doi: 10.1073/pnas.101617298. Epub 2001 Apr 17. Proc Natl Acad Sci U S A. 2001. PMID: 11309512 Free PMC article. - Gene methylation in gastric cancer.
Qu Y, Dang S, Hou P. Qu Y, et al. Clin Chim Acta. 2013 Sep 23;424:53-65. doi: 10.1016/j.cca.2013.05.002. Epub 2013 May 10. Clin Chim Acta. 2013. PMID: 23669186 Review. - DNA methylation changes and multiple myeloma.
Ng MH, Wong IH, Lo KW. Ng MH, et al. Leuk Lymphoma. 1999 Aug;34(5-6):463-72. doi: 10.3109/10428199909058473. Leuk Lymphoma. 1999. PMID: 10492069 Review.
Cited by
- Activating the dark genome to illuminate cancer vaccine targets.
Kwok DW, Okada H, Costello JF. Kwok DW, et al. Nat Genet. 2024 Sep;56(9):1770-1771. doi: 10.1038/s41588-024-01850-3. Nat Genet. 2024. PMID: 39223317 No abstract available. - Multiomics analysis identifies oxidative phosphorylation as a cancer vulnerability arising from myristoylation inhibition.
Beauchamp E, Gamma JM, Cromwell CR, Moussa EW, Pain R, Kostiuk MA, Acevedo-Morantes C, Iyer A, Yap M, Vincent KM, Postovit LM, Julien O, Hubbard BP, Mackey JR, Berthiaume LG. Beauchamp E, et al. J Transl Med. 2024 May 7;22(1):431. doi: 10.1186/s12967-024-05150-6. J Transl Med. 2024. PMID: 38715059 Free PMC article. - Targeting histone deacetylases in head and neck squamous cell carcinoma: molecular mechanisms and therapeutic targets.
Xu M, Hou Y, Li N, Yu W, Chen L. Xu M, et al. J Transl Med. 2024 May 3;22(1):418. doi: 10.1186/s12967-024-05169-9. J Transl Med. 2024. PMID: 38702756 Free PMC article. Review. - Cancer epigenetics: from laboratory studies and clinical trials to precision medicine.
Yu X, Zhao H, Wang R, Chen Y, Ouyang X, Li W, Sun Y, Peng A. Yu X, et al. Cell Death Discov. 2024 Jan 15;10(1):28. doi: 10.1038/s41420-024-01803-z. Cell Death Discov. 2024. PMID: 38225241 Free PMC article. Review. - Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony-stimulating Factor Therapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Study from a Single-Center.
Kong FC, Qi L, Zhou YL, Yu M, Huang WF, Li F. Kong FC, et al. Curr Med Sci. 2023 Dec;43(6):1151-1161. doi: 10.1007/s11596-023-2805-7. Epub 2023 Dec 7. Curr Med Sci. 2023. PMID: 38057538
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous